<DOC>
	<DOCNO>NCT02581124</DOCNO>
	<brief_summary>Study evaluate effect lapatinib , breast cancer resistance protein ( BCRP ) inhibitor , pharmacokinetics ( PK ) JTZ-951 evaluate safety tolerability JTZ-951 administer alone one hour administration lapatinib .</brief_summary>
	<brief_title>Study Evaluate Effect Lapatinib Pharmacokinetics JTZ-951 Subjects With End-stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Subjects end stage renal disease hemodialysis Postdialysis body weight &gt; 45.0 kg BMI 18.0 40.0 kg/m2 ( inclusive ) Subjects positive test result HBsAg ( hepatitis B surface antigen ) , HCV antibody HIV antibody Subjects know history liver failure liver surgery Subjects history current clinically significant chronic acute blood loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>JTZ-951</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>